<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/ACFBA6B3-2436-4FF7-8F53-771DA2EA0EAD"><gtr:id>ACFBA6B3-2436-4FF7-8F53-771DA2EA0EAD</gtr:id><gtr:name>Synpromics Ltd</gtr:name><gtr:address><gtr:line1>NINE, Edinburgh Bioquarter</gtr:line1><gtr:line2>9, Little France Road</gtr:line2><gtr:postCode>EH16 4UX</gtr:postCode><gtr:region>Scotland</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/ACFBA6B3-2436-4FF7-8F53-771DA2EA0EAD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>ACFBA6B3-2436-4FF7-8F53-771DA2EA0EAD</gtr:id><gtr:name>Synpromics Ltd</gtr:name><gtr:address><gtr:line1>NINE, Edinburgh Bioquarter</gtr:line1><gtr:line2>9, Little France Road</gtr:line2><gtr:postCode>EH16 4UX</gtr:postCode><gtr:region>Scotland</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>150455.0</gtr:offerGrant><gtr:projectCost>250758.0</gtr:projectCost></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A87B8669-28D7-4030-8E57-B00F5EC45B1F" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>A87B8669-28D7-4030-8E57-B00F5EC45B1F</gtr:id><gtr:name>Ingenza Limited</gtr:name><gtr:address><gtr:line1>Wallace Building
Roslin Biocentre</gtr:line1><gtr:city>Roslin</gtr:city><gtr:postCode>EH25 9PP</gtr:postCode><gtr:region>Scotland</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>139321.0</gtr:offerGrant><gtr:projectCost>232202.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/8D8BBC8A-8BB3-4C88-A255-61B5518AA7B5"><gtr:id>8D8BBC8A-8BB3-4C88-A255-61B5518AA7B5</gtr:id><gtr:firstName>Michael</gtr:firstName><gtr:surname>Roberts</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=101791"><gtr:id>E4B98E39-4DC6-4131-B26C-BB04B606741E</gtr:id><gtr:title>Adaptable Synthetic Promoters to Optimise Industrial Competitiveness of Engineered Yeast</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Collaborative R&amp;D</gtr:grantCategory><gtr:grantReference>101791</gtr:grantReference><gtr:abstractText>The collaboration between Synpromics and Ingenza is focused on developing proprietary protein production systems in engineered yeast strains that improve on currently available alternatives by incorporating novel synthetic promoter constructs rationally designed to drive optimal gene expression. The enabling technology that the project aims to deliver will address significant limitations faced by a wide range of bio-manufacturers using yeast-based expression, enabling the more efficient production of protein products and intermediary production enzymes. The combination of Synpromics's and Ingenza's innovative technologies and expertise is expected to validate a platform on which to build an even broader range of solutions to yeast-based expression challenges, thereby establishing in the UK a leading capability in synthetic biology and sustainable industrial bioprocessing.</gtr:abstractText><gtr:fund><gtr:end>2015-11-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2014-06-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>289776</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">101791</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>